REFERENCES
1 Ponikowski P, Voors AA, Anker SD et al. ESC
Scientific Document Group. 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure. Eur Heart J (2016) 37,
2129–2200
2 Schrage B, Uijl A, Benson L, Westermann D et al.
Association Between Use of Primary-Prevention Implantable
Cardioverter-Defibrillators and Mortality in Patients With Heart
Failure: A Prospective Propensity Score-Matched Analysis From the
Swedish Heart Failure Registry. Circulation. 2019;140(19):1530-1539.
3 Gasparini M, Proclemer A, Klersy C et al. Effect of
long-detection interval vs standard-detection interval for implantable
cardioverter-defibrillators on antitachycardia pacing and shock
delivery: the ADVANCE III randomized clinical trial.JAMA. 2013;
309:1903–1911.
4 Moss AJ, Schuger C, Beck CA et al. Reduction in
inappropriate therapy and mortality through ICD programming. N Engl J
Med. 2012; 367:2275–2283.
5 Ruwald AC, Schuger C, Moss AJ et al. Mortality
reduction in relation to implantable cardioverter defibrillator
programming in the Multicenter Automatic Defibrillator Implantation
Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm
Electrophysiol. 2014; 7:785–792.
6 Saeed M, Hanna I, Robotis D et al. Programming
implantable cardioverter-defibrillators in patients with primary
prevention indication to prolong time to first shock: results from the
PROVIDE study. J Cardiovasc Electrophysiol. 2014; 25:52–59.
7 Wilkoff BL, Ousdigian KT, Sterns LD et al. A
comparison of empiric to physician-tailored programming of implantable
cardioverter-defibrillators: results from the prospective randomized
multicenter EMPIRIC trial.J Am Coll Cardiol. 2006; 48:330–339. doi:
10.1016/j.jacc.2006.03.037.CrossrefMedlineGoogle Scholar
8 Wilkoff BL, Ousdigian KT, Sterns LD et al. A
comparison of empiric to physician-tailored programming of implantable
cardioverter-defibrillators: results from the prospective randomized
multicenter EMPIRIC trial.J Am Coll Cardiol. 2006; 48:330–339.
9 Gasparini M, Menozzi C, Proclemer A et al. A
simplified biventricular defibrillator with fixed long detection
intervals reduces implantable cardioverter defibrillator (ICD)
interventions and heart failure hospitalizations in patients with
non-ischaemic cardiomyopathy implanted for primary prevention: the
RELEVANT [Role of long dEtection window programming in patients with
LEft VentriculAr dysfunction, Non-ischemic eTiology in primary
prevention treated with a biventricular ICD] study. Eur Heart J. 2009;
30:2758–2767.
10 Tan VH, Wilton SB, Kuriachan V et al. Impact of
programming strategies aimed at reducing nonessential implantable
cardioverter defibrillator therapies on mortality: a systematic review
and meta-analysis. Circ Arrhythm Electrophysiol. 2014; 7:164–170.
11 Wilkoff BL, Fauchier L, Stiles MK et al. 2015
HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable
cardioverter-defibrillator programming and testing. Europace. 2016
Feb;18(2):159-83. doi: 10.1093/europace/euv411
12 Thøgersen AM, Larsen JM, Johansen JB et al. Failure
to Treat Life-Threatening Ventricular Tachyarrhythmias in Contemporary
Implantable Cardioverter-Defibrillators: Implications for Strategic
Programming. Circ Arrhythm Electrophysiol. 2017 Sep;10(9). pii: e005305.
13 Stiles MK, Fauchier L, Morillo CA et al. 2019
HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement
on optimal implantable cardioverter-defibrillator programming and
testing. Europace. 2019 Sep 1;21(9):1442-1443.
14 Gradaus R, Bode-Schnurbus L, Weber M et al. Effect
of ventricular fibrillation duration on the defibrillation threshold in
humans. Pacing Clin Electrophysiol 2002;25: 14–9.
15 Wathen M, DeGroot P, Sweeney M et al. Prospective
Randomized Multicenter Trial of Empirical Antitachycardia Pacing Versus
Shocks for Spontaneous Rapid Ventricular Tachycardia in Patients With
Implantable Cardioverter-Defibrillators - Pacing Fast Ventricular
Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial Results.
Circulation. 2004 Oct 26;110(17):2591-6.
16 Dallaglio PD, Anguera I, Martínez Ferrer JB et al.
Shock Reduction With Antitachycardia Pacing Before and During Charging
for Fast Ventricular Tachycardias in Patients With Implantable
Defibrillators. Rev Esp Cardiol (Engl Ed). 2018 Sep;71(9):709-717.
17 Sears SF, Todaro JF, Urizar G et al. Assessing the
psychosocial impact of the ICD: a national survey of implantable
cardioverter defibrillator health care providers. Pacing Clin
Electrophysiol 2000;23:939 – 45.
18 Desai AS, Fang JC, Maisel WH et al. Implantable
defibrillators for the prevention of mortality in patients with
nonischemic cardiomyopathy: a meta-analysis of randomized controlled
trials. JAMA 2004; 292:2874–2879.
19 Greene SJ, Fonarow GC, DeVore AD et al. Titration
of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J
Am Coll Cardiol. 2019;73(19):2365-2383.
20 Le HH, El-Khatib C, Mombled M et al. Impact of
Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart
Failure and Post-Myocardial Infarction Patients: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016 18;11(2):
e0145958.
LEGENDS OF FIGURES
Figure 1 – Programming settings in the new programming group
Figure 2 – Study design and enrolment
Figure 3 –Kaplan-Meier survival curve for the primary endpoint (any
therapy)